Sign In
Section Navigation
Common TitleDAWNING
Official Title A Phase 3b, Randomized, Open-label Study of the Antiviral Activity and Safety of Dolutegravir Compared to Lopinavir/Ritonavir Both Administered With Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1 Infected Adult Subjects With Treatment Failure on First Line Therapy
Phase Phase IIIB
ClinicalTrials.gov NCT02227238
Treatments
Dolutegravir
Dolutegravir Tivicay

Dolutegravir

Tradename:TivicayOther Names:DTGClass:Integrase Strand Transfer Inhibitors (INSTI)
Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryViiV Healthcare
References
  • Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019;19:253-64.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.